anti-TNFα Therapeutic Drug Monitoring

Therapeutic drug monitoring (TDM) strategies are implemented on the assumption that clinical effects correlate better with drug concentrations in serum rather than with dose.

TDM is often employed when using drugs with a narrow therapeutic window, where the concentrations producing the desired beneficial effects are relatively close to the concentrations which produce toxic results.

Quantum Blue® Compact bench top lateral flow reader for rapid, quantitative determination of calprotectin levels and TDM assays. Ideal POC test
Quantum Blue™ Reader III. Compact reader for rapid, quantitative determination of calprotectin & TDM with lateral flow assays. Ideal for POC
Serum Adalimumab Quantitative lateral-flow test for BÜHLMANN Quantum Blue reader for measuring trough Adalimumab levels. Range 1.3.35µg/ml
Serum Adalimumab Quantitative lateral-flow test for BÜHLMANN Quantum Blue reader for trough Adalimumab levels. Range 1.3.35µg/ml. 10 Tests
Serum Anti-Adalimumab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Adalimumab 10 tests
Serum Anti-Adalimumab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Adalimumab 25 tests
Serum Anti-Infliximab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Infliximab
Serum Anti-Infliximab lateral-flow test for the BÜHLMANN Quantum Blue reader for measuring trough antibody levels for Infliximab 10 tests
Serum Infliximab Quantitative lateral-flow test used with BÜHLMANN Quantum Blue® reader for measuring trough Infliximab levels. Range 0.4-20µg/ml
Serum Infliximab Quantitative lateral-flow test used with BÜHLMANN Quantum Blue® reader for trough Infliximab levels. Range 0.4-20µg/ml. 10 Tests